Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Cetuximab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Feb 2024 Planned End Date changed from 1 Oct 2023 to 19 Jan 2022.
- 26 Feb 2024 Planned primary completion date changed from 1 Jan 2022 to 19 Jan 2022.
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.